Possible role for chlorpheniramine in the treatment of L-DOPA induced dyskinesia in Parkinson's disease.
Karamanakos
Petros N
PN
Pappas
Periklis
P
Marselos
Marios
M
D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D002744:Chlorpheniramine / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D007980:Levodopa / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D017366:Serotonin Receptor Agonists; D002744:Chlorpheniramine; D007980:Levodopa